1. World Health Organization. The World health report: 2004: changing history.
2. Global tuberculosis report. Geneva: World Health Organization; 2018.
3. UNAIDS/WHO. AIDS epidemic update. Geneva: Joint United Nations Programme on HIV/AIDS and World Health Organization; 2007.
4. UNAIDS (2017) ‘Ending AIDS:Progress towards 90-90-90 targets’
5. UNAIDS ‘AIDSinfo’(accessed sugust 2019).
6. Rehle TM, Hallett TB, Shisana O, Pillay-van Wyk V, Zuma K, Carrara H, et al. A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008. PloS one. 2010;5(6):e11094
7. HIV/AIDS JUNPo, HIV/Aids JUNPo. 90-90-90: an ambitious treatment target to help end the AIDS epidemic. Geneva: UNAIDS. 2014.
8.“Five-year survival probabilities after ART start at 3 hospitals in Guyana,” in Proceedings of the Caribbean HIV Conference, I. Wanyeki, D. Cole, G. Sills, and P. Bass, Eds., Nassau, TheBahamas, November 2011.
9. J. Ayalew,H. Moges, and A. Worku, “Identifying factors related to the survival of AIDS patients under the follow-up of Antiretroviral Therapy (ART): the case of South Wollo,” International Journal of Data Envelopment Analysis and Operations Research, vol. 1, no. 2, pp. 21–27, 2014.
10. UNAIDS, “UNAIDS report on the global AIDS epidemic,” Tech. Rep., UNAIDS, Geneva, Switzerland, 2013.
11. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22 (5):1897-908.
12. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design.
AIDS 2005; 19 (18): 2141-8
13. Weiser SD, Tuller DM, Frongillo EA, Senkungu J, Mukiibi N, Bangsberg DR. Food insecurity as a barrier to sustained antiretroviral therapy adherence in Uganda. PloS one. 2010;5(4).
14. Emenyonu N, Sheri DW, Tuller D, Bangsberg D, Ware N, Weiser S, Emenyonu SN, Tuller DM, Bangsberg DR, Emenyonu N, Senkungu J. Transportation Costs Impede Sustained Adherence and Access to HAART in a Clinic Population in Southwestern Uganda: A Qualitative Study.
15. Gilbert L, Walker L. ‘My biggest fear was that people would reject me once they knew my status…’: stigma as experienced by patients in an HIV/AIDS clinic in Johannesburg, South Africa. Health & social care in the community. 2010 Mar;18(2):139-46.
16. Namutebi AM, Kamya MR, Byakika-Kibwika P. Causes and outcome of hospitalization among HIV-infected adults receiving antiretroviral therapy in Mulago hospital, Uganda. African health sciences. 2013;13(4):977-85.
17. Gyuse AN, Bassey IE, Udonwa NE, Okokon IB, Philip-Ephraim EE. HIV/AIDS related mortality among adult medical patients in a tertiary health institution in South–South, Nigeria. Asian Pacific Journal of Tropical Medicine. 2010 Feb 1;3(2):141-4.
18. Okome-Nkoumou M, Guiyedi V, Ondounda M, Efire N, Clevenbergh P, Dibo M, Dzeing-Ella A. Opportunistic diseases in HIV-infected patients in Gabon following the administration of highly active antiretroviral therapy: a retrospective study. The American journal of tropical medicine and hygiene. 2014 Feb 5;90(2):211-5.
19. Iroezindu MO, Ofondu EO, Hausler H, Van Wyk B. Prevalence and Risk factors for opportunistic infections in HIV patients receiving antiretroviral therapy in a resource-limited setting in Nigeria. J AIDS Clin Res. 2013. https ://doi.org/10.4172/2155-6113.
20. Manisha G, Swapna D, Srikanth T, Madhura N, Preeti G. Incidence of common opportunistic infections in HIV-infected individuals in Pune, India: analysis by stages of immunosuppression represented by CD4 counts. Int J Infect Dis. 2009; 13:1–8.
21. Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T et al. A trial of early antiretroviral and isoniazid preventive therapy in Africa. N Engl J Med. 2015; 373(9): 808-22.
22. Durovni B, Saraceni V, Moulton LH, Pacheco AG, Cavalcante SC, King BS et al. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis. 2013; 13(10): 852-8.
23. Saavedra A, Campinha-Bacote N, Hajjar M, Kenu E, Gillani FS, Obo-Akwa A, Lartey M, Kwara A. Causes of death and factors associated with early mortality of HIV-infected adults admitted to Korle-Bu Teaching Hospital. Pan African Medical Journal. 2017; 27 (1).
24. Kreuzer KA, Rockstroh JK. Pathogenesis and pathophysiology of anemia in HIV infection. Annals of hematology. 1997 Dec 1; 75 (5-6):179-87.
25. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW, Adult/Adolescent Spectrum of Disease Group. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood. 1998 Jan 1; 91 (1):301-8.
26. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach: executive summary. Geneva: World Health Organization; 2002.
27. Melku M, Addis Z, Alem M, Enawgaw B. Prevalence and predictors of maternal anemia during pregnancy in Gondar, Northwest Ethiopia: an institutional based cross-sectional study. Anemia. 2014; 2014.
28. Anastasija S, Inga A, Baiba R. Cryptococcosis in HIV–Infected Hospitalized Patients in Latvia. Journal of Scientific Research and Reports. 2019 Aug 3:1-0.
29. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, Denning DW, Loyse A, Boulware DR. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. The Lancet infectious diseases. 2017 Aug 1; 17 (8):873-81.
30. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, Denning DW, Loyse A, Boulware DR. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. The Lancet infectious diseases. 2017 Aug 1; 17 (8):873-81.
31. Havlir DV, Dubé MP, McCutchan JA, Forthal DN, Kemper CA, Dunne MW, Parenti DM, Kumar PN, White Jr AC, Witt MD, Nightingale SD. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clinical infectious diseases. 1998 Dec 1; 27 (6):1369-75.
32. Chetchotisakd P, Sungkanuparph S, Thinkhamrop B, Mootsikapun P, Boonyaprawit P. A multicentre, randomized, double‐blind, placebo‐controlled trial of primary cryptococcal meningitis prophylaxis in HIV‐infected patients with severe immune deficiency. HIV medicine. 2004 May; 5 (3):140-3.
33. Szczech LA, Hoover DR, Feldman JG, Cohen MH, Gange SJ, Goozé L, Rubin NR, Young MA, Cai X, Shi Q, Gao W. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clinical infectious diseases. 2004 Oct 15; 39 (8):1199-206.
34. Rao TS, Filippone EJ, Nicastri AD, Landesman SH, Frank E, Chen CK, Friedman EA. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. New England Journal of Medicine. 1984 Mar 15; 310 (11):669-73.
35. Verhelst D, Monge M, Meynard JL, Fouqueray B, Mougenot B, Girard PM, Ronco P, Rossert J. Fanconi syndrome and renal failure induced by tenofovir: a first case report. American Journal of Kidney Diseases. 2002 Dec 1; 40 (6):1331-3.
36. Moore DM, Yiannoutsos CT, Musick BS, Tappero J, Degerman R, Campbell J, Were W, Kaharuza F, Alexander LN, Downing R, Mermin J. Determinants of early and late mortality among HIV-infected individuals receiving home-based antiretroviral therapy in rural Uganda. Journal of acquired immune deficiency syndromes (1999). 2011 Nov 1; 58 (3):299.
37. Hartung TK, Chimbayo D, van Oosterhout JJ, Chikaonda T, van Doornum GJ, Claas EC, Melchers WJ, Molyneux ME, Zijlstra EE. Etiology of suspected pneumonia in adults admitted to a high-dependency unit in Blantyre, Malawi. The American journal of tropical medicine and hygiene. 2011 Jul 1; 85 (1):105-12.
38. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Annals of internal medicine. 2001 Jul 3; 135 (1):17-26.
39. Zahar JR, Robin M, Azoulay E, Fieux F, Nitenberg G, Schlemmer B. Pneumocystis carinii pneumonia in critically ill patients with malignancy: a descriptive study. Clinical infectious diseases. 2002 Oct 15; 35 (8):929-34.
40. Agaba PA, Digin E, Makai R, Apena L, Agbaji OO, Idoko JA, Murphy R, Kanki P. Clinical characteristics and predictors of mortality in hospitalized HIV-infected Nigerians. The Journal of Infection in Developing Countries. 2011 Mar 4; 5 (05):377-82
41. Mzileni MO, Longo-Mbenza B, Chephe TJ. Mortality and causes of death in HIV-positive patients receiving antiretroviral therapy at Tshepang Clinic in Doctor George Mukhari Hospital. Pol Arch Med Wewn. 2008 Oct 1; 118 (10):548-54.
42. Ramjan R, Calmy A, Vitoria M et al. Systematic review and meta-analysis: patient and programme impact of fixed-dose combination antiretroviral therapy. Trop Med Int Health2014;
43. Biadgilign S, Reda AA, Digaffe T. Predictors of mortality among HIV infected patients taking antiretroviral treatment in Ethiopia: a retrospective cohort study. AIDS research and therapy. 2012 Dec; 9 (1):15.
44. Andrew N Phillips, PhD;Schlomo staszswski, MD; Rainer Weber, MD et al. HIV Viral load Response to antiretroviral therapy according to the baseline CD4 cell count and Viral load 2001;286920):2560-2567.
45. Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. American journal of kidney diseases. 2011 May 1; 57 (5):773-80.